Mitomycin intravesical - Halozyme

Drug Profile

Mitomycin intravesical - Halozyme

Alternative Names: Chemophase; Hyaluronidase-mitomycin; Mitomycin-hyaluronidase; Recombinant human hyaluronidase/mitomycin

Latest Information Update: 17 Apr 2013

Price : $50

At a glance

  • Originator Halozyme Therapeutics
  • Class Antineoplastics; Aziridines; Carbamates; Cytostatic antibiotics; Indoles; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Bladder cancer

Most Recent Events

  • 01 Dec 2011 No development reported - Phase-I/II for Bladder cancer in USA (Intravesicular)
  • 01 Aug 2009 Halozyme Therapeutics completes a Phase-I trial in Bladder cancer in USA (NCT00782587)
  • 31 Oct 2008 Halozyme Therapeutics initiates enrolment in a USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top